2022
DOI: 10.1016/j.arabjc.2022.104039
|View full text |Cite
|
Sign up to set email alerts
|

Design, synthesis, and biological evaluation of (E)-N′-substitute-4-((4-pyridylpyrimidin-2-yl)amino)benzohydrazide derivatives as novel potential CDK9 inhibitors

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
3
0

Year Published

2023
2023
2023
2023

Publication Types

Select...
4

Relationship

0
4

Authors

Journals

citations
Cited by 4 publications
(3 citation statements)
references
References 24 publications
0
3
0
Order By: Relevance
“…Again, we refluxed with compounds such as 2, 3, and 4-pyridyl-propenone. The resulting products reacted with hydrazine to form the reported products, which, followed by a condensation reaction with suitable aldehydes, gave hydrazone products [85]. Carboxamide and carbothioamide derivatives were yielded by first refluxing p-aminobenzoate with cyan-amide in the presence of conc.…”
Section: Synthesis Of Anticancer Agentsmentioning
confidence: 99%
See 2 more Smart Citations
“…Again, we refluxed with compounds such as 2, 3, and 4-pyridyl-propenone. The resulting products reacted with hydrazine to form the reported products, which, followed by a condensation reaction with suitable aldehydes, gave hydrazone products [85]. Carboxamide and carbothioamide derivatives were yielded by first refluxing p-aminobenzoate with cyan-amide in the presence of conc.…”
Section: Synthesis Of Anticancer Agentsmentioning
confidence: 99%
“…Reasonable activity was exhibited by compound Benzo[d]thiazolyl)methoxyphenyl-triazolyl methyl aniline against cancer cell lines with GI 50 ranges from 0.55 to 1.2 µM [84]. Evaluation of synthetic compounds as CDK9 inhibitors exhibited exceptional antiproliferative activities of the compound amino-benzohydrazide against cancer cells with IC 50 values ranging between 0.57 ± 0.02 µM and 1.73 ± 0.09 µM [85]. Among all of the synthesized structures, excellent antagonist activity was shown by compound Nbutyl-2-( 4-((4-(pyridin-4-yl)pyrimidin-2-yl)amino)benzoyl)hydrazine-1-carboxamide having EC 50 = 1.68 ± 0.22 µM.…”
Section: Anticancer Activitymentioning
confidence: 99%
See 1 more Smart Citation